VZ - AbbVie Arch Capital Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades' | Benzinga
On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. (NASDAQ: GILD) is an inexpensive way to give biotech exposure.
Gilead Sciences, last month, said that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK) for approximately $21.25 million, at $1.4167 per share.
Jim Lebenthal of Cerity Partners said AbbVie Inc. (NYSE: ABBV) is a "good one" in the healthcare space.
AbbVie remained confident in ...